Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

60 results about "Viral illness" patented technology

Viral Illness. Viral illnesses are usually simply referred to as a virus or viral infection. They occur when a microscopic infectious agent enters the body. Here the virus attacks the body, causing an immune response and illness.

Tricyclic compound, and preparation method therefor and use thereof

A tricyclic compound, and a preparation method therefor and the use thereof. The present invention relates to a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, genetic disorders, hormone-related diseases, metabolic disorders, organ-transplantation-related diseases, immunodeficiency disorders, destructive bone diseases, proliferative disorders, infectious diseases, cell-death-related conditions and cardiovascular diseases. Each substituent in general formula (I) is as defined in the description.
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD

Active substances for medical use

To provide an amine of a specific compound, a carbonic acid adduct and a pharmaceutical composition for use in the treatment of atypical pneumonia and in the therapy of viral diseases.SOLUTION: The present invention provides an amine (AM) of the general formula (I) for use in the treatment of atypical pneumonia and in the therapy of viral diseases.SELECTED DRAWING: None
Owner:INFLAMED PHARM GMBH

Application of salinomycin in preparation of medicine for resisting monkey pox virus infection

The invention relates to the technical field of medicines, in particular to application of salinomycin in preparation of oral medicines for preventing or treating monkey pox virus (MPXV) infection. Salinomycin is a polyether antibiotic produced by actinomycetes. It is found for the first time that salinomycin can efficiently inhibit monkey pox virus infection on the cell culture level, and can significantly improve the survival rate of mice infected with monkey pox virus in small animal living bodies. More importantly, salinomycin can be administered by oral administration, has good bioavailability and safety, and provides a brand new treatment means for monkey pox virus infection. The medicinal value of salinomycin in resistance to monkey pox virus infection is reported for the first time at home and abroad, and the application prospect of salinomycin in the field of viral disease treatment is expanded.
Owner:THE NAVAL MEDICAL UNIV OF PLA

Aqueous composition comprising avermectins

An aqueous composition is provided which comprises at least one surface modifier selected from a group consisting of cellulose derivatives, in particular hydroxypropylmethyl cellulose, methylcellulose and hydroxypropylcellulose, polyvinylpyrrolidones and derivatives thereof, alginates, carrageenan, collagens, polyoxyethylene-polyoxypropylene copolymers, polyalkylene glycols, lecithins, phospholipids, pegylated phospholipids, gelatine, cholesterol, casein, tragacanth, pectins, gums, especially gum arabic, dextran, polyoxyethylen stearates, polyvinyl alcohol, polyethylene glycols, triethanolamine, tocopherol-polyethylene glycols and combinations thereof in an amount from 0.05% by weight to 15% by weight, based on the total weight of the composition, at least one active pharmaceutical ingredient selected from the group of avermectins in an amount from 2% by weight to 15% by weight, based on the total weight of the composition, having a mean particle size of 0.01 µm to 20 µm, and water in an amount from 70% by weight to 97.9% by weight, based on the total weight of the composition. Preferably, the at least one active pharmaceutical ingredient selected from the group of avermectins is ivermectin. Further, the aqueous composition is preferably for use in a pharmaceutical composition or medicament, wherein preferably for the use in the prevention or treatment of viral diseases, in particular for use in the prevention or treatment of a SARS-Covid-2 infection or of a HIV infection.
Owner:HWI PHARMA SERVICES GMBH

Oligosaccharide compositions and methods of use thereof for treating viral infections

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for treating respiratory viral illnesses, such as COVID-19.
Owner:KALEIDO BIOSCIENCES INC +1

DsRNA of targeted IPV NS1 gene and application of dsRNA

The invention discloses dsRNA (double-stranded ribonucleic acid) of a targeted IPV (infectious precocity virus) NS1 gene and application of the dsRNA. The dsRNA disclosed by the invention consists of a positive-sense strand of which the nucleotide sequence is as shown in SEQ ID NO.1 and an antisense strand of which the nucleotide sequence is as shown in SEQ ID NO.2. The dsRNA is injected into the macrobrachium rosenbergii infected with the IPV virus, so that the load of the IPV virus can be obviously reduced by utilizing the dsRNA, and the growth inhibition of the IPV virus on the macrobrachium rosenbergii is relieved. On the basis, the dsRNA or a biological material capable of expressing the dsRNA, such as a cell or a strain capable of expressing the dsRNA, can be used for preparing a reagent for inhibiting the IPV virus, so that viral diseases caused by IPV virus infection are prevented and treated. The composition is beneficial to prevention and treatment of IPV virus related diseases, and promotes the long and stable development of the macrobrachium rosenbergii breeding industry.
Owner:SUN YAT SEN UNIV +1

Vidofludimus for use in the treatment or prevention of viral diseases

The present invention relates to a compound according to Formula (I)or a salt, solvate and / or a hydrate thereof, wherein said compound inhibits dihydroorotate dehydrogenase (DHODH), for use in the treatment and prevention of viral infection. A preferred example is viral infection caused by coronavirus, in particular betacoronavirus, more particular SARS-CoV-2 and mutated versions thereof.
Owner:IMMUNIC AG

Pentacyclic triterpenoid c-glycoside, method for producing and use of the same

To provide pentacyclic triterpenoid C-glycoside, a method for producing the glycoside, and use of the glycoside.SOLUTION: Provided is a compound expressed by formula I. The compound can be used for producing a drug for treating metabolic diseases such as diabetes mellitus, and viral diseases caused by an influenza virus or a coronavirus.SELECTED DRAWING: None
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES

Nitrogen-containing heteroaromatic ring degradation agent as well as preparation method and application thereof

PendingCN119490481AOrganic active ingredientsNervous disorderAutoimmune conditionImmunodeficiency disease
The invention belongs to the field of medicines, and particularly relates to a nitrogen-containing heteroaromatic ring degradation agent as well as a preparation method and application thereof. Particularly, the invention relates to a compound as shown in a general formula (I), a preparation method thereof and a pharmaceutical composition containing the compound, the invention also relates to the application of the compound in preparation of medicines for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplantation-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases and the like. The invention also relates to the application of the medicine for treating diseases related to cell death or cardiovascular diseases. Wherein each substituent in the general formula (I) is as defined in the specification.
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD

Treatment of viral infection, disease or disorder using a selective sir agonist

The subject invention provides a method for treating, reducing the incidence, suppressing or inhibiting a viral infection, disease, disorder or symptoms thereof in a subject in need thereof comprising administering to the subject a selective S1R agonist. In another aspect, the viral disease is COVID-19, and the selective S1R agonist is pridopidine or pharmaceutically acceptable salt thereof.
Owner:PRILENIA NEUROTHERAPEUTICS LTD

Therapy guidance and / or therapy monitoring for treatment with angiotensin-receptor-agonist and / or precursor thereof

To provide a therapy guidance and / or therapy monitoring for treatment with an angiotensin-receptor-agonist and / or a precursor thereof.SOLUTION: Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, wherein the disease is selected from the group consisting of heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and wherein the subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.SELECTED DRAWING: None
Owner:4ティーン4ファーマシューティカルズゲゼルシャフトミットベシュレンクテルハフツング

Aqueous composition comprising avermectins

PCT designated stage expiredWO2025008199A1Organic active ingredientsSolution deliveryDiseaseCarrageenan
An aqueous composition is provided which comprises at least one surface modifier selected from a group consisting of cellulose derivatives, in particular hydroxypropylmethyl cellulose, methylcellulose and hydroxypropylcellulose, polyvinylpyrrolidones and derivatives thereof, alginates, carrageenan, collagens, polyoxyethylene-polyoxypropylene copolymers, polyalkylene glycols, lecithins, phospholipids, pegylated phospholipids, gelatine, cholesterol, casein, tragacanth, pectins, gums, especially gum arabic, dextran, polyoxyethylen stearates, polyvinyl alcohol, polyethylene glycols, triethanolamine, tocopherol-polyethylene glycols and combinations thereof in an amount from 0.05% by weight to 15% by weight, based on the total weight of the composition, at least one active pharmaceutical ingredient selected from the group of avermectins in an amount from 2% by weight to 15% by weight, based on the total weight of the composition, having a mean particle size of 0.01 µm to 20 µm, and water in an amount from 70% by weight to 97.9% by weight, based on the total weight of the composition. Preferably, the at least one active pharmaceutical ingredient selected from the group of avermectins is ivermectin. Further, the aqueous composition is preferably for use in a pharmaceutical composition or medicament, wherein preferably for the use in the prevention or treatment of viral diseases, in particular for use in the prevention or treatment of a SARS-Covid-2 infection or of a HIV infection.
Owner:HWI PHARMA SERVICES GMBH

Antiviral traditional Chinese medicine composition and preparation method thereof

The invention relates to an antiviral traditional Chinese medicine composition and a preparation method thereof. The formula comprises bothriospermum chinense, ginseng, powdered sugar, honey and cocklebur fruit. The preparation method comprises the following steps: 1) preparing raw materials, and performing crushing treatment; 2) decocting for the first time; (3) decocting for the second time, and combining decoction; and 4) concentrating. 5) adding auxiliary materials; and 6) drying to prepare powder. The traditional Chinese medicine composition has the advantages that the traditional Chinese medicine composition is prepared through scientific compatibility of various Chinese herbal medicines with the effects of resisting viruses, tonifying qi, relieving a cough, moistening the lung and the like through a special process, has a remarkable antiviral effect and a good taste, can effectively prevent and treat viral diseases and improve the immunity of the organism, and is suitable for being used by a wide range of people.
Owner:SUIXIAN HAIPING AGRICULTURAL DEVELOPMENT CO LTD

Traditional Chinese medicine composition for resisting viruses of livestock and poultry and application of traditional Chinese medicine composition

The invention provides an antiviral traditional Chinese medicine composition for livestock and poultry and application thereof, and relates to the technical field of traditional Chinese medicine pharmacy for livestock and poultry. The traditional Chinese medicine composition provided by the invention is used for preparing medicines for preventing or treating viral diseases of livestock and poultry. The traditional Chinese medicine composition is prepared from 10 to 30 parts of cortex magnoliae officinalis, 10 to 30 parts of herba taraxaci, 10 to 30 parts of airpotato yam rhizome, 10 to 30 parts of oriental stephania root, 1 to 10 parts of radix aconiti lateralis preparata, 10 to 30 parts of herba commelinae, 10 to 30 parts of caulis clematidis armandii, 10 to 30 parts of rhizoma alismatis, 10 to 30 parts of radix ophiopogonis and 10 to 30 parts of radix adenophorae. The traditional Chinese medicine composition can improve the body immune organ index, enhance the body immunity and improve the body disease resistance; the traditional Chinese medicine composition has a remarkable treatment effect on various viral diseases such as avian influenza, infectious bursal disease, Newcastle disease, gosling gout, porcine circovirus disease, transmissible gastroenteritis, epidemic diarrhea, rotavirus infection, bovine viral diarrhea, rabbit hemorrhagic disease, canine coronavirus diarrhea, feline plague and mink viral enteritis, the death rate is reduced, the production performance is improved, and the like.
Owner:HENAN PROVINCIAL INST OF MODERN CHINESE VETERINARY MEDICINE +3

Application of flubendazole in preparation of drugs for resisting flavivirus virus infection

The invention discloses an application of flubendazole in preparation of a medicine for resisting flavivirus virus infection. According to the invention, the established Zika virus intercellular transmission model is processed by using the flubendazole, and the result shows that the flubendazole can inhibit the intercellular transmission of the Zika virus. On the basis, the combination of the flubendazole and the neutralizing antibody MZ54 of the targeted Zika virus E protein discovers that the inhibition effect on Zika virus transmission can be remarkably improved through the combination of the flubendazole and the neutralizing antibody MZ54. Therefore, the flubendazole can be used for preparing a medicine for resisting flavivirus infection, and the flubendazole can be combined with a neutralizing antibody of a targeted flavivirus to realize the effect of resisting virus infection. The invention is beneficial for inhibiting the transmission of Zika virus, is beneficial for preventing and treating viral diseases caused by flavivirus virus infection, and has important significance for maintaining public health and safety.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

A Chinese medicine composition for preventing and treating peste des petits ruminants and animal viral diseases and its application

The present invention relates to the field of animal medicine, and discloses a Chinese medicine composition and application for preventing and treating peste des petits ruminants and animal viral diseases. The Chinese medicine composition comprises the following components: indigo, coptis root, phellodendron, charcoal, mint, platycodon, catechu, isatis root, astragalus, codonopsis, angelica, epimedium and liquorice; the Chinese medicine composition is applied to viral diseases of livestock, poultry and aquatic animals. The Chinese medicine composition of the present invention can not only prevent and treat peste des petits ruminants, but also reduce the probability of viral diseases of livestock, poultry and aquatic animals. In addition, the raw materials involved in the Chinese medicine composition do not contain any antibiotics, prohibited ingredients and animal-derived ingredients, achieving the goals of green, safety and high efficiency, and providing a reliable technical support for accelerating the development of antibiotic-free breeding and green food in my country.
Owner:HUNAN GREAT WORLD VENTURE BIOTECHNOLOGY CO LTD

Alternative method for preparing [[[4-phenyl-5-alkoxycarbonyl-2-thiazol-2-yl-1,4-dihydropyrimidin-6-yl]methyl]-3-oxo-5,6,8,8a-tetrahydro-1H-imidazo[1,5-a]pyrazin-2-yl]-carboxylic acid

The present invention relates to an alternative method for synthesizing a compound of formula (I) or a pharmaceutically acceptable salt or diastereomer thereof, R 1 is phenyl, which is unsubstituted or substituted by one, two or three independently selected from halogen and C 1‑6 Alkyl substituents are substituted; R 2 C 1‑6 Alkyl; R 3 C x H 2x ‑; x is 1, 2, 3, 4, 5, 6 or 7; the compound or its pharmaceutically acceptable salt or diastereomer can be used to prevent and treat viral diseases associated with hepatitis B infection or diseases caused by hepatitis B infection in patients.
Owner:F HOFFMANN LA ROCHE & CO AG

Pyrimidine derivative or salt thereof used as TLR7 / 8 agonist, pharmaceutical composition thereof, and use thereof

PCT designated stage expiredWO2025039995A1Organic active ingredientsOrganic chemistryTLR8Disease
A pyrimidine derivative represented by formula (I-1), formula (I-2), formula (II-1) or formula (II-2), or a stereoisomer, tautomer, isotope derivative, hydrate, solvate, prodrug, and pharmaceutically acceptable salt thereof. The pyrimidine derivative can be used as an effective TLR7 and / or TLR8 agonist, and has the characteristics of good selectivity, high activity, and good safety. Also provided are a preparation method for the pyrimidine derivative and a pharmaceutical composition thereof. The compound or the pharmaceutical composition thereof can be used for preparing drugs for preventing or treating the following diseases: infectious diseases, respiratory system diseases, immune-related diseases, viral diseases or tumors.
Owner:MIRACURE BIOTECHNOLOGY LTD

Compound containing aromatic ring pyridone amide

The invention provides a compound containing aromatic ring pyridone amide, and particularly provides an aromatic ring pyridone amide compound with a structure as shown in a general formula I, and a racemate, an R-isomer, an S-isomer, a pharmaceutically acceptable salt or a mixture of the racemate, the R-isomer, the S-isomer and the pharmaceutically acceptable salt thereof. The compound provided by the invention can be used as a 3CL protease (also known as main protease) inhibitor, and is especially used for treating viral diseases with 3CL protease, such as diseases caused by SARS-CoV-2, SARS-CoV, MERS-CoV, norovirus and the like. # imgabs0 #
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES +1

Vidofludimus for use in the treatment or prevention of viral diseases

The present invention relates to a compound according to Formula (I) or a salt, solvate and / or a hydrate thereof, wherein said compound inhibits dihydroorotate dehydrogenase (DHODH), for use in the treatment and prevention of viral infection. A preferred example is viral infection caused by coronavirus, in particular betacoronavirus, more particular SARS-CoV-2 and mutated versions thereof.
Owner:IMMUNIC AG

Subunit vaccine for porcine reproductive and respiratory syndrome virus

The invention relates to the technical field of biology, in particular to a porcine reproductive and respiratory syndrome virus subunit vaccine. Through bioinformatics analysis and experimental verification, the antigen protein with excellent immunogenicity is obtained through screening, and the amino acid sequence of the antigen protein is shown as SEQ ID NO: 1. The subunit vaccine constructed on the basis of the protein can effectively induce mice to generate high-level neutralizing antibodies, the effect of the subunit vaccine is remarkably better than that of commercial control vaccines, the mice can be stimulated to generate strong humoral immunity and cellular immunity at the same time, and the induced immune response type is mainly Th2 type. Further research shows that the antigen protein and the virus structural protein E + M are combined for immunization, and the immune effect of the structural protein can be remarkably enhanced. The subunit vaccine developed by the invention provides a new thought for research and development of novel vaccines for resisting PRRSV and other viral diseases.
Owner:SHIHEZI UNIVERSITY

Targeted protein degradation compound as well as preparation method and application thereof

PendingCN120981450AOrganic active ingredientsOrganic chemistryAutoimmune conditionImmunodeficiency disease
The invention relates to a targeted protein degradation compound as well as a preparation method and application thereof, and belongs to the field of medicines. Specifically, the invention relates to a compound as shown in a general formula (I), a preparation method thereof and a pharmaceutical composition containing the compound, the invention also relates to the application of the compound in preparation of medicines for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, hereditary diseases, hormone-related diseases, metabolic diseases, organ transplantation-related diseases, immunodeficiency diseases, destructive bone diseases, proliferative diseases, infectious diseases and the like. The invention also relates to the application of the medicine for treating diseases related to cell death or cardiovascular diseases. Wherein each substituent in the general formula (I) is as defined in the specification. B-L-K (I)
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD

N-1 triazole substituted imidazoquinolines, conjugates thereof, and methods

Disclosed are 1H-imidazo[4,5-c]quinolin-4-amine compounds having a triazole ring substituent at the 1-position, salts thereof, conjugates thereof, pharmaceutical compositions containing the compounds and conjugates, and methods for making the compounds and conjugates. Methods of using the compounds and conjugates as immune response modifiers to induce cytokine biosynthesis in humans and animals and in the treatment of diseases, including viral and neoplastic diseases, are also described.
Owner:SOLVENTUM INTELLECTUAL PROPERTIES CO

Use of il-27 antagonists for the treatment of EBV-driven b lymphoproliferative diseases

PendingUS20260193338A1Infected cellAutoantibody
Upon EBV infection, the inventors found that IL-27 is produced by infected B lymphocytes and IL27RAIL-27 interaction is required for in vitro maintenance and expansion of EBV-transformed B cells, potentially explaining the favorable outcome of the EBV viral disease in IL27RA-deficient patients. In addition, the inventors identified neutralizing anti-IL27 autoantibodies in individuals who developed sporadic infectious mononucleosis, thus possibly phenocopying the IL27RA deficiency. Collectively, these results demonstrate the critical role of IL27-IL27RA axis in immunity to EBV, but also the hijacking of this defense by EBV to promote expansion of infected cells. The IL27-IL27RA could therefore represent a novel therapeutic target to inhibit EBV-driven B lymphoproliferative diseases.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +4

Indole-based small molecule antivirals against SARS-COV-2

PCT designated stageWO2025203062A1Organic chemistryAntiviralsDiseaseAntiviral drug
The present invention relates to the preparation of indole-based compounds in free form or an acceptable salt form potential therapeutic target as an antiviral agent against SARS-Cov2. The indole-based small molecules are, capable of antiviral activity in RT-qPCR and cell-based assay in SARS-CoV-2 infected VERO E6 cells, that may ultimately be used to achieve improved human health in patients against covid- 19 or other similar viral diseases.
Owner:COUNCIL OF SCI & IND RES